Kidney Failure, Acute Clinical Trial
Official title:
Comparison of ANCA and Anti-GBM Auto-antibodies Removal Kinetics Between Plasma Exchanges and Immunoadsorption in Patients With ANCA-associated Vasculitis or Anti-GBM Disease
Anti-neutrophil cytoplasmic antibodies (ANCA), directed against myeloperoxidase (MPO) and against proteinase 3 (PR3), have a pathogenic role during ANCA (AAV) vasculitis. Glomerular basement membrane (MBG) antibodies also have a direct pathogenic role in Goodpasture's syndrome and anti-MBG antibody glomerulonephritis (GN). In some patients, the severity of renal and / or pulmonary involvement justifies the rapid purification of these autoantibodies by an apheresis procedure, while waiting for the effect of immunosuppressive treatments aimed at reducing their production. During vasculitis, plasma exchange (PE) is recommended in patients with severe renal impairment or intra-alveolar hemorrhage (2012 KDIGO Clinical Practice Guideline for Glomerulonephritis). Given certain disadvantages related to plasma exchanges (low volume of purified plasma, non-selective technique for immunoglobulins (Ig), need for replacement solute, induction of coagulation disorders), immunoadsorption (IA), already used in transplantation, has been developed in these indications. IA has indeed greater selectivity for Ig with a probable better purification capacity due to higher volumes of plasma treated per session. The price of IA is however higher than that of EP. These two apheresis techniques, EP and IA, are commonly used in France during severe forms of vasculitis ANCA or anti-MBG, without the superiority of one or the other has been demonstrated. As a result of higher plasma volumes being purified, AI may allow faster purification of pathogenic antibodies. No studies to date have specifically compared the purification kinetics of these antibodies between EP and IA. The CINEVAS study (VAScularite Antibody Purification CINetic) is a multicentric pilot study whose main objective is to compare the purification kinetics of ANCA (anti-MPO or anti-PR3) and / or anti- MBG in patients treated with EP versus those treated with IA
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00982527 -
Fenoldopam in Pediatric Cardiac Surgery
|
Phase 3 | |
Completed |
NCT00908843 -
Prevention of Contrast Induced Nephropathy (NIC) by Intravenous Versus Oral Rehydration
|
N/A | |
Completed |
NCT00654992 -
Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery
|
Phase 2/Phase 3 | |
Completed |
NCT05407272 -
Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care
|
N/A | |
Not yet recruiting |
NCT05399420 -
Study of Kidney Circulating Cell-free DNA in Patients With Acute Kidney Failure
|
||
Recruiting |
NCT04334707 -
Kidney Precision Medicine Project
|
||
Completed |
NCT04072432 -
A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3-4 Chronic Kidney Disease
|
Phase 1 | |
Recruiting |
NCT00230412 -
Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study)
|
N/A | |
Completed |
NCT00148044 -
Uremic Toxins of Patients With Acute Kidney Failure
|
N/A | |
Active, not recruiting |
NCT04450095 -
Effects of Endothelin Receptor Antagonist on Ischemic Kidney Injury During Nephron Sparing Surgery
|
Phase 2 | |
Terminated |
NCT05747053 -
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
|
||
Completed |
NCT03353389 -
Review of Trend in Incidence and Characteristics of Hospital-acquired Acute Kidney Injury in Hospital Selayang
|
||
Completed |
NCT03727581 -
Ultrasound for Guidewire Detection
|
||
Completed |
NCT00912184 -
Study Comparing High Cut-off Haemofiltration With Standard Haemofiltration in Acute Renal Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT00522756 -
Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy
|
Phase 3 | |
Completed |
NCT00484354 -
Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery
|
Phase 2 | |
Terminated |
NCT00316576 -
Angiotensin-Converting Enzyme Polymorphism and Acute Renal Failure (ECAREA)
|
N/A | |
Completed |
NCT00122018 -
An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery
|
Phase 2 | |
Unknown status |
NCT01359722 -
N-acetylcysteine to Prevent Renal Failure
|
N/A | |
Completed |
NCT00286273 -
Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration
|
Phase 4 |